| abstract |
The invention relates to 7-oxoprostacyclin derivatives of Formula I ##STR1## wherein R 1 is the residue OR 3 wherein R 3 can mean hydrogen or alkyl of 1-10 carbon atoms optionally substituted by halogen, phenyl, C 1 -C 4 -alkoxy or C 1 -C 4 -dialkylamino, or the residue NHR 4 meaning an alkanoyl or alkanesulfonyl residue of respectively 1-10 carbon atoms, n W is a hydroxymethylene or a ##STR2## group wherein the OH-group can be respectively esterified with a benzoyl or alkanoic acid residue of 1-4 carbon atoms or etherified with a tetrahydropyranyl, tetrahydrofuranyl, (C 1 -C 4 -alkoxy)-C 1 -C 4 -alkyl or tri-(C 1 -C 4 -alkyl)-silyl residue, wherein the free or modified OH-group can be in the α- or β- position, n D is a straight-chain or branched alkylene group of 1-5 carbon atoms, n R 2 is a straight-chain or branched alkyl group of 1-6 carbon atoms, n R 5 is a hydroxy group which can be esterified with an alkanoic acid residue of 1-4 carbon atoms or etherified with a tetrahydropyranyl, tetrahydrofuranyl, (C 1 -C 4 -alkoxy)-C 1 -C 4 -alkyl or tri-(C 1 -C 4 -alkyl)silyl residue, n X is an oxygen atom or the residue --CH 2 --, and, if R 3 means hydrogen, the salts thereof n with physiologically compatible bases, to processes for their preparation, and to their use as medicinal agents. |